Libang Instrument was ordered to pay 91 million yuan in damages

Shenzhen Mindray Biomedical Electronics Co., Ltd. ("Mindray") announced on April 18, 2011 that Mindray has submitted a new batch of patent infringement complaints to the Shenzhen Intermediate People's Court, appealing to Shenzhen Libang Precision. Instrument Co., Ltd. (hereinafter referred to as “Daibang”) infringed related patents; at the same time, Mindray increased the amount of claims for the change of litigation requests filed by the Shenzhen Intermediate People’s Court on April 8th.

Mindray stated that on April 8, 2011, Mindray’s lawsuit request was based on Libang’s 2010 “M8 patient monitor”, “M9 patient monitor”, “M80 patient monitor” and “M50 patient monitoring. After calculating the alleged infringement amount of the "Yiyi" product, the amount of compensation for the above four products from 2008 to 2009 was calculated and the amount of compensation increased accordingly, thus changing the claim. At the same time, "M8A patient monitor", "M8B patient monitor", "M9A patient monitor", "M9B patient monitor", and "DUS 3 all-digital ultrasonic diagnostic system" of the medical imaging service of LIANGBO , "DUS 6 Full Digital Ultrasound Diagnosis System", "DUS 3 Vet Full Digital Ultrasound Diagnosis System", and "DUS 6 Vet Full Digital Ultrasound Diagnosis System" were also suspected of infringing Mindray's related invention patents from 2008 to 2010. At this point, from 2008 to 2010, as the two major business of Libang, the guardianship business and many products of the ultrasound imaging business were all suspected of violating the intellectual property rights of Mindray. In order to prevent Dibang from transferring assets, the resulting verdict or ruling was difficult to enforce, and Mindray also filed an application for property preservation in Shenzhen Intermediate People's Court.

According to the financial data publicly disclosed by the company, the company's main business sales revenue from 2008 to 2010 totaled 718.7722 million yuan, while the cumulative sales revenue of the suspected infringing guardian products and ultrasound imaging business products totaled 298,570,200 yuan, accounting for a total of From 2008 to 2010, 41.54% of the total sales revenue of the main business. Based on this, Mindray believes that "the damages caused by the suspected infringement of Libang Company to the Mindray Company are extremely significant." In this lawsuit filed with the Shenzhen Intermediate People's Court, Mindray asked Ribang to “immediately stop the infringement; immediately stop manufacturing, promise sales, and sell infringing products; destroy inventories of infringing products and semi-finished products; and destroy infringing products. Advertising and promotional materials, deleting the promotion and advertising of the product on the Internet; and requesting Libang to compensate a total of RMB 81 million for infringement of patent rights from 2008 to 2010 and RMB 10 million for infringement of commercial secrets. yuan".

As the world's first-class medical device R&D manufacturer and the world's third largest provider of patient monitoring equipment, Mindray always manages its technological innovation capabilities as a core asset. It is understood that since its establishment 20 years ago, Mindray has consistently invested 10% of its sales revenue in product innovation and R&D. It has also established a R&D management platform that is in sync with international standards, and has launched more than 80 items of self-owned knowledge. Property rights products. By the end of 2010, it had filed more than 1,100 domestic and international patent applications and had granted more than 550 patents. While adhering to R&D investment, Mindray has placed special emphasis on the protection of intellectual property rights. Any violation of its intellectual property rights is not acceptable to Mindray.

About Mindray: Shenzhen Mindray Bio-Medical Electronics Co., Ltd. is a global leader in medical device R&D and manufacturing. Its headquarters is located in Shenzhen, China. The Group has branch offices in the United States and major global markets. China-centered R&D and manufacturing platforms and strong R&D and marketing networks established around the world have helped Mindray to launch a wide range of products that cover the four major areas of life information and support, clinical testing and reagents, digital ultrasound, and radiology imaging.